The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1016/j.ymgme.2013.01.021 http://repositorio.unifesp.br/handle/11600/36233 |
Resumo: | Objectives: the objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects.Methods: MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels.Results: Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean +/- SD height z-scores were -5.6 +/- 3.1 as determined by the CDC growth charts. Mean +/- SD from the 6-minute-walk-test was 212.6 +/- 1522 m, revealing limitations in functional endurance testing, and 30.0 +/- 24.0 stairs/min for the 3-minute-stair-climb test. Respiratory function showed limitations comparable to MPS VI patients; mean +/- SD was 1.2 +/- 0.9 1 based on forced vital capacity and 34.8 +/- 25.5 l/min based on maximum voluntary ventilation. Mean urinary keratan sulfate (uKS) was elevated for all ages, and negatively correlated with age. Higher uKS correlated with greater clinical impairment based on height z-scores, endurance and respiratory function tests. the MPS Health Assessment Questionnaire reveals impairments in mobility and activities of daily living in comparison to an age-matched control population.Conclusions: MPS IVA is a multisystem disorder with a continuum of clinical presentation. All affected individuals experience significant functional limitations and reduced quality of life. Older patients have more severe exercise and respiratory capacity limitations, and more frequent cardiac pathology illustrating the progressive nature of disease. (C) 2013 Elsevier Inc. All rights reserved. |
id |
UFSP_c419785404f15a2421de07b44e7d1372 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/36233 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjectsMPSMorquioGALNSLysosomal storage disorderEnduranceRespiratory functionObjectives: the objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects.Methods: MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels.Results: Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean +/- SD height z-scores were -5.6 +/- 3.1 as determined by the CDC growth charts. Mean +/- SD from the 6-minute-walk-test was 212.6 +/- 1522 m, revealing limitations in functional endurance testing, and 30.0 +/- 24.0 stairs/min for the 3-minute-stair-climb test. Respiratory function showed limitations comparable to MPS VI patients; mean +/- SD was 1.2 +/- 0.9 1 based on forced vital capacity and 34.8 +/- 25.5 l/min based on maximum voluntary ventilation. Mean urinary keratan sulfate (uKS) was elevated for all ages, and negatively correlated with age. Higher uKS correlated with greater clinical impairment based on height z-scores, endurance and respiratory function tests. the MPS Health Assessment Questionnaire reveals impairments in mobility and activities of daily living in comparison to an age-matched control population.Conclusions: MPS IVA is a multisystem disorder with a continuum of clinical presentation. All affected individuals experience significant functional limitations and reduced quality of life. Older patients have more severe exercise and respiratory capacity limitations, and more frequent cardiac pathology illustrating the progressive nature of disease. (C) 2013 Elsevier Inc. All rights reserved.Childrens Hosp & Res Ctr Oakland, Oakland, CA USAMC Univ Mainz, Ctr Pediat & Adolescent Med, Mainz, GermanyUniv Fed Rio Grande do Sul, Dept Genet, HCPA, Med Genet Serv, Porto Alegre, RS, BrazilINAGEMP, Porto Alegre, RS, BrazilHop Necker Enfants Malad, Paris, FranceMackay Mem Hosp, Taipei, TaiwanMackay Med Coll, Taipei, TaiwanAz Osped S Gerardo, Monza, ItalyHop Femme Mere Enfant, Lyon, FranceAnn & Robert H Lurie Childrens Hosp, Chicago, IL USANorthwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USABirmingham Childrens Hosp NHS Fdn Trust, Birmingham, W Midlands, EnglandMcGill Univ, Ctr Hlth, Montreal, PQ, CanadaUniversidade Federal de São Paulo, São Paulo, BrazilUniv Manchester, Cent Manchester Univ Hosp, Manchester, Lancs, EnglandHosp Ninos Cordoba, Cordoba, ArgentinaGreat Ormond St Hosp Sick Children, London WC1N 3JH, EnglandUniv Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, NetherlandsUniversidade Federal de São Paulo, São Paulo, BrazilWeb of ScienceBioMarin Pharmaceutical Inc.National Center for Research ResourcesFondazione Pierfranco and Luisa Mariani of MilanoNational Center for Research Resources: 5 M01 RR-01271Elsevier B.V.Childrens Hosp & Res Ctr OaklandMC Univ MainzUniv Fed Rio Grande do SulINAGEMPHop Necker Enfants MaladMackay Mem HospMackay Med CollAz Osped S GerardoHop Femme Mere EnfantAnn & Robert H Lurie Childrens HospNorthwestern UnivBirmingham Childrens Hosp NHS Fdn TrustMcGill UnivUniversidade Federal de São Paulo (UNIFESP)Univ ManchesterHosp Ninos CordobaGreat Ormond St Hosp Sick ChildrenUniv AmsterdamHarmatz, PaulMengel, Karl EugenGiugliani, RobertoValayannopoulos, VassiliLin, Shuan-PeiParini, RossellaGuffon, NathalieBurton, Barbara K.Hendriksz, Christian J.Mitchell, JohnMartins, Ana Maria [UNIFESP]Jones, SimonGuelbert, NorbertoVellodi, AshokHollak, CarlaSlasor, PeterDecker, Celeste2016-01-24T14:31:37Z2016-01-24T14:31:37Z2013-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion54-61application/pdfhttp://dx.doi.org/10.1016/j.ymgme.2013.01.021Molecular Genetics and Metabolism. San Diego: Academic Press Inc Elsevier Science, v. 109, n. 1, p. 54-61, 2013.10.1016/j.ymgme.2013.01.021WOS000318055100010.pdf1096-7192http://repositorio.unifesp.br/handle/11600/36233WOS:000318055100010engMolecular Genetics and Metabolisminfo:eu-repo/semantics/openAccesshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policyreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-07T05:26:18Zoai:repositorio.unifesp.br/:11600/36233Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-07T05:26:18Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects |
title |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects |
spellingShingle |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects Harmatz, Paul MPS Morquio GALNS Lysosomal storage disorder Endurance Respiratory function |
title_short |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects |
title_full |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects |
title_fullStr |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects |
title_full_unstemmed |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects |
title_sort |
The Morquio A Clinical Assessment Program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects |
author |
Harmatz, Paul |
author_facet |
Harmatz, Paul Mengel, Karl Eugen Giugliani, Roberto Valayannopoulos, Vassili Lin, Shuan-Pei Parini, Rossella Guffon, Nathalie Burton, Barbara K. Hendriksz, Christian J. Mitchell, John Martins, Ana Maria [UNIFESP] Jones, Simon Guelbert, Norberto Vellodi, Ashok Hollak, Carla Slasor, Peter Decker, Celeste |
author_role |
author |
author2 |
Mengel, Karl Eugen Giugliani, Roberto Valayannopoulos, Vassili Lin, Shuan-Pei Parini, Rossella Guffon, Nathalie Burton, Barbara K. Hendriksz, Christian J. Mitchell, John Martins, Ana Maria [UNIFESP] Jones, Simon Guelbert, Norberto Vellodi, Ashok Hollak, Carla Slasor, Peter Decker, Celeste |
author2_role |
author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Childrens Hosp & Res Ctr Oakland MC Univ Mainz Univ Fed Rio Grande do Sul INAGEMP Hop Necker Enfants Malad Mackay Mem Hosp Mackay Med Coll Az Osped S Gerardo Hop Femme Mere Enfant Ann & Robert H Lurie Childrens Hosp Northwestern Univ Birmingham Childrens Hosp NHS Fdn Trust McGill Univ Universidade Federal de São Paulo (UNIFESP) Univ Manchester Hosp Ninos Cordoba Great Ormond St Hosp Sick Children Univ Amsterdam |
dc.contributor.author.fl_str_mv |
Harmatz, Paul Mengel, Karl Eugen Giugliani, Roberto Valayannopoulos, Vassili Lin, Shuan-Pei Parini, Rossella Guffon, Nathalie Burton, Barbara K. Hendriksz, Christian J. Mitchell, John Martins, Ana Maria [UNIFESP] Jones, Simon Guelbert, Norberto Vellodi, Ashok Hollak, Carla Slasor, Peter Decker, Celeste |
dc.subject.por.fl_str_mv |
MPS Morquio GALNS Lysosomal storage disorder Endurance Respiratory function |
topic |
MPS Morquio GALNS Lysosomal storage disorder Endurance Respiratory function |
description |
Objectives: the objectives of this study are to quantify endurance and respiratory function and better characterize spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects.Methods: MorCAP was a multicenter, multinational, cross sectional study amended to be longitudinal in 2011. Each study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels.Results: Data from the first visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean +/- SD height z-scores were -5.6 +/- 3.1 as determined by the CDC growth charts. Mean +/- SD from the 6-minute-walk-test was 212.6 +/- 1522 m, revealing limitations in functional endurance testing, and 30.0 +/- 24.0 stairs/min for the 3-minute-stair-climb test. Respiratory function showed limitations comparable to MPS VI patients; mean +/- SD was 1.2 +/- 0.9 1 based on forced vital capacity and 34.8 +/- 25.5 l/min based on maximum voluntary ventilation. Mean urinary keratan sulfate (uKS) was elevated for all ages, and negatively correlated with age. Higher uKS correlated with greater clinical impairment based on height z-scores, endurance and respiratory function tests. the MPS Health Assessment Questionnaire reveals impairments in mobility and activities of daily living in comparison to an age-matched control population.Conclusions: MPS IVA is a multisystem disorder with a continuum of clinical presentation. All affected individuals experience significant functional limitations and reduced quality of life. Older patients have more severe exercise and respiratory capacity limitations, and more frequent cardiac pathology illustrating the progressive nature of disease. (C) 2013 Elsevier Inc. All rights reserved. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-05-01 2016-01-24T14:31:37Z 2016-01-24T14:31:37Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1016/j.ymgme.2013.01.021 Molecular Genetics and Metabolism. San Diego: Academic Press Inc Elsevier Science, v. 109, n. 1, p. 54-61, 2013. 10.1016/j.ymgme.2013.01.021 WOS000318055100010.pdf 1096-7192 http://repositorio.unifesp.br/handle/11600/36233 WOS:000318055100010 |
url |
http://dx.doi.org/10.1016/j.ymgme.2013.01.021 http://repositorio.unifesp.br/handle/11600/36233 |
identifier_str_mv |
Molecular Genetics and Metabolism. San Diego: Academic Press Inc Elsevier Science, v. 109, n. 1, p. 54-61, 2013. 10.1016/j.ymgme.2013.01.021 WOS000318055100010.pdf 1096-7192 WOS:000318055100010 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Molecular Genetics and Metabolism |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy |
dc.format.none.fl_str_mv |
54-61 application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier B.V. |
publisher.none.fl_str_mv |
Elsevier B.V. |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268395256807424 |